Liquid Biopsy Market to Grow at Massive CAGR of 13.49%

A recent market analysis conducted by Future Market Insights (FMI) projects that the global liquid biopsy market is expected generate US$ 1,026 Million in revenue in 2021. By 2031, the market is anticipated to reach US$ 3,637 Million, growing at a 13.49% CAGR.

Liquid Biopsy Market Overview:

The global liquid biopsy market report begins by defining liquid biopsy and various types of markers used in liquid biopsy. It is followed by an overview of market dynamics of the global liquid biopsy market, which includes FMI’s analysis of key trends, drivers, restraints and opportunities, and reimbursement scenario that is influencing the growth of the liquid biopsy market. It also includes an insight into case-studies and product pipeline. Impact analysis of key growth drivers and restraints based on a weighted average model have been included in the global liquid biopsy market report after detailed analysis of individual regions to better equip readers with meaningful insights on ongoing developments in the oncology market.

The primary factors fueling demand for liquid biopsy diagnostic tests are growing incidences of lung, gastrointestinal and breast cancer. Other factors driving demand for liquid biopsy tests are increasing inclination of oncologists and physician to opt for non-invasive diagnostic procedures, reluctance of the patients to go painful biopsies and increase in the demand of personalized medicine.  Whereas increasing number of test launches and entry of regional players also drives the market for liquid biopsy tests. However, a primary factor hampering growth of the liquid biopsy market is its penetration owing lower awareness of blood tests to detect cancer.

Key Market Segmentation:

  • By Marker Type
    • CTCs (Circulating tumour Cells)
    • ctNA (Circulating tumour Nucleic Acids)
    • Exosomes
  • By Sample Type
    • Blood
    • Urine
    • Others (Plasma, Saliva, CSF)
  • By Disease Indication
    • Lung Cancer
    • Gastrointestinal Cancer
    • Prostate Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Leukemia
    • Others
  • By End-User
    • Hospitals
    • Cancer Institutes
    • Academic Institutes
    • Diagnostic Centers

The next section of the report highlights liquid biopsy market by region and provides market outlook for 2016–2026. The report also discusses key regional trends contributing to the revenue growth of the liquid biopsy tests worldwide, as well as analyses the impact of drivers and restraints in each region. Key regions assessed in this report include North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan (APEJ), Japan and Middle East & Africa (MEA).

Another key feature of this report is the analysis of key segments in terms of absolute dollar opportunity. This is overlooked while forecasting the market. However, absolute dollar opportunity is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective, in the global liquid biopsy market.

Detailed profiles of the liquid biopsy tests developing companies are also included in the scope of the report to evaluate their long- and short-term strategies, key offerings, SWOT analysis, and recent developments in the global liquid biopsy market.

Key Companies Profiled in the Study:

  • Qiagen N.V.
  • Trovagene, Inc
  • Janssen Global Services, LLC
  • MDxHealth SA
  • Natera, Inc
  • F. Hoffmann-La Roche Ltd
  • Silicon Biosystems
  • Pathway Genomics Corporation
  • Sysmex Corporation

For More Information:

Comments are closed